CN112437811A - Recombinant NAD synthetase, gene and application thereof - Google Patents

Recombinant NAD synthetase, gene and application thereof Download PDF

Info

Publication number
CN112437811A
CN112437811A CN201980044146.7A CN201980044146A CN112437811A CN 112437811 A CN112437811 A CN 112437811A CN 201980044146 A CN201980044146 A CN 201980044146A CN 112437811 A CN112437811 A CN 112437811A
Authority
CN
China
Prior art keywords
recombinant
nad
nicotinamide
amino acid
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980044146.7A
Other languages
Chinese (zh)
Other versions
CN112437811B (en
Inventor
张章
张琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bontac Invitrolife Bio Technology Shenzhen Co ltd
Bontac Bio-Engineering (shenzhen) Co ltd
Original Assignee
Bontac Invitrolife Bio Technology Shenzhen Co ltd
Bontac Bio-Engineering (shenzhen) Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bontac Invitrolife Bio Technology Shenzhen Co ltd, Bontac Bio-Engineering (shenzhen) Co ltd filed Critical Bontac Invitrolife Bio Technology Shenzhen Co ltd
Publication of CN112437811A publication Critical patent/CN112437811A/en
Application granted granted Critical
Publication of CN112437811B publication Critical patent/CN112437811B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C12N1/185—Saccharomyces isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/21—Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/85—Saccharomyces
    • C12R2001/865—Saccharomyces cerevisiae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provides a recombinant NAD synthetase, a gene and an application thereof. The enzyme comprises a nicotinamide mononucleotide adenylyltransferase structural domain derived from haemophilus influenzae and a nicotinamide ribokinase structural domain derived from any one of human beings, saccharomyces cerevisiae, escherichia coli and salmonella typhimurium, and can be applied to large-scale production of NAD by taking NR and ATP as raw materials in industrial production.

Description

Recombinant NAD synthetase, gene and application thereof Technical Field
The invention relates to the technical field of biological enzyme catalysis and genetic engineering, in particular to a recombinant NAD synthetase artificially obtained by a genetic engineering technical means, a gene thereof and industrial application of the recombinant NAD synthetase in large-scale catalytic NR and ATP conversion production.
 Background
NAD synthase, which is a Nicotinamide Adenine Dinucleotide (NAD) synthase, also known as NADR or NADR, is an enzyme that catalyzes the conversion of a substrate to Nicotinamide Adenine Dinucleotide.
NAD is a physiological substance present in almost all living cells including human cells, has no toxic side effects on human bodies, is a cofactor of many enzymes that catalyze oxidation-reduction reactions, is involved in various physiological activities such as cellular substance metabolism, energy synthesis, cellular DNA repair, etc., is a control marker in energy-generating chains in mitochondria, and is called coenzyme i.
The NAD has wide application, can be used for chemical catalytic reaction, raw material medicine production, health product industry, cosmetic industry and the like, and has large market demand. At present, two methods for industrially producing NAD generally comprise a chemical method and a biological catalysis method, and the biological catalysis method gradually becomes a mainstream because of the advantages of mild reaction conditions, energy conservation, environmental protection, no organic solvent residue and the like compared with the chemical method.
The biological catalysis method for producing the NAD specifically comprises the step of producing the NAD by taking Nicotinamide Mononucleotide (NMN) and Adenosine Triphosphate (ATP) as raw materials under the catalysis action of nicotinamide mononucleotide adenyl transferase (NMNAT). This method has a drawback that NMN is extremely expensive, resulting in extremely high production cost of NAD and no competitive advantage in the market. Therefore, the industry has adopted a biocatalytic method in which Nicotinamide Riboside (NR), a precursor of NMN, is substituted for NMN, while a biocatalyst, Nicotinamide Ribokinase (NRK), for catalyzing the conversion of NR into NMN is added. This method has disadvantages in that two enzymatic reactions are required, resulting in a prolonged reaction time and an increase in the number of production operations. The NAD synthetase has the advantage that NAD can be synthesized by one-step catalysis by taking NR and ATP as raw materials.
Naturally occurring NAD synthetases have now been found in a variety of organisms, e.g., from Salmonella typhimurium (A)Salmonella typhimurium) In (1)stNadR derived from Haemophilus influenzae (b) ((b))Haemophilus influenzae) In (1)hiNadR, derived from Escherichia coli (E. coli)Escherichia coli) In (1)ecNadR, and the like. There is a significant bias in the activity of these naturally occurring NAD synthetases, however, e.g.,hiNadR has higher activity of converting NMN into NAD, but has weaker activity of converting NR into NMN, andstNadR、 ecthe NadR activity is exactly opposite. Therefore, when the naturally-existing NAD synthetase is used for catalyzing NR and ATP conversion to produce NAD, the conversion rate is low, the yield of NAD production is low, the cost is high, and the conditions for industrial application cannot be met, so that the application of NAD synthetase in large-scale industrial production is limited.
 Technical problem
In view of the defects of the prior art mentioned in the background art, the invention aims to overcome the technical problem that the conversion rate of the NAD synthetase catalyzing NR and the conversion of ATP into NAD is low, and develop a recombinant NAD synthetase suitable for large-scale industrial application, thereby solving the technical problems of high production cost and complex operation existing in the existing NAD industrial production method.
 Technical solution
In order to achieve the purpose, the inventor conducts a large amount of tests and screening on the currently known genes, fuses the screened known target gene fragments by utilizing the technical means of genetic engineering so as to obtain a series of recombinant NAD synthetase, and finally screens out fusion products in which the enzymatic activity is remarkably improved. Based on this, the present invention provides a recombinant NAD synthase comprising a nicotinamide mononucleotide adenyl transferase domain derived from haemophilus influenzae and a nicotinamide ribokinase domain derived from any one of human, saccharomyces cerevisiae, escherichia coli and salmonella typhimurium.
In the recombinant NAD synthetase provided by the invention, Haemophilus influenzae, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium refer to all types of strains under the name of the strain, namely, corresponding enzyme domains of all types of strains under the Haemophilus influenzae, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium are all applicable to the invention.
Preferably, in the recombinant NAD synthase provided by the present invention, the nicotinamide ribokinase domain is fused to the C-terminus of the nicotinamide mononucleotide adenylyltransferase domain.
More preferably, in the recombinant NAD synthase provided by the present invention, the nicotinamide ribokinase domain is fused to the nicotinamide mononucleotide adenylyltransferase domain via a flexible linker, and the sequence of the flexible linker is GSGSGSGS. The connecting peptide segment is specially designed according to the structural characteristics of two fused enzyme structural domains and is determined through multiple screening and experimental verification, and compared with other connecting peptide segments, the connecting peptide segment can play a role in enhancing protein expression.
More preferably, in the recombinant NAD synthase provided by the present invention, the amino acid sequence of the nicotinamide mononucleotide adenylyltransferase domain derived from Haemophilus influenzae is accession number P44308 in UniProt [52-224]]Is namedhiNMNAT; the amino acid sequences of the nicotinamide ribokinase domain from human, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium are sequentially the UniProt with the accession numbers Q9NWW6, Q9NPI5, P53915, P27278[230-]And P2458 [230-]The corresponding nomenclature is in turnhNRK1、 hNRK2、 yNRK1、 ecNRK andstNRK。
more preferably, the amino acid sequence of the recombinant NAD synthase provided by the present invention is as set forth in SEQ ID NO: 4 to SEQ ID NO: shown in fig. 8.
The invention also provides a gene sequence which encodes the recombinant NAD synthetase provided by the invention.
The invention also provides a biological material which comprises a recombinant vector, a recombinant cell or a recombinant microorganism, and the biological material contains the gene sequence provided by the invention. That is, the biomaterial of the present invention is a recombinant vector containing the gene sequence of the present invention, or a recombinant cell containing the gene sequence of the present invention, or a recombinant microorganism containing the gene sequence of the present invention.
In addition, the invention also provides the application of the recombinant NAD synthetase, namely the recombinant NAD synthetase is applied to industrial production and is used for producing NAD in a large scale by taking NR and ATP as raw materials.
 Advantageous effects
Compared with the prior art, the invention has the following advantages:
1. compared with NAD synthetase existing in the nature, the enzyme activity of the recombinant NAD synthetase provided by the invention is obviously improved, through experimental detection, the enzyme activity is 3.5-65 times of that of common NAD synthetase existing in the nature, and the yield of NAD generated by catalyzing NR and ATP conversion is increased by more than 400%, so that the recombinant NAD synthetase is suitable for large-scale chemical industry production of NAD.
2. Compared with the existing method for producing NAD by biological catalysis, when the recombinant NAD synthetase is used for producing NAD, the NAD can be produced by one-step catalysis by taking NR and ATP as raw materials, the feeding cost is reduced, the reaction time can be shortened, the industrial operation steps are reduced, and the production cost is greatly reduced.
 Modes for carrying out the invention
The present invention will be described in further detail with reference to specific examples, which are illustrative of the present invention and are not to be construed as being limited thereto. Unless otherwise specified, the starting materials and reagents used in the examples of the present invention are commercially available, and those not specifically mentioned in the examples are carried out under conventional conditions or conditions recommended by the manufacturer.
1. Construction of NAD synthetase plasmid
(1) Naturally occurring NAD synthase plasmids
The following primer pairs (SEQ ID NO: 9 to SEQ ID NO: 14) were designed
ecNadR-1-NdeⅠ-up：CCCATATGTCGTCATTTGATTACCTG
ecNadR-end-XhoⅠ-dn：CCCTCGAGTTATCTCTGCTCCCCCATCATCT
stNadR-1-NdeⅠ-up：CCCATATGTCATCGTTCGACTATCTCAA
stNadR-end-XhoⅠ-dn：CCCTCGAGTTATCCCTGCTCGCCCATCATC
hiNadR-52-NdeⅠ-up：CCCATATGTCAAAAACAAAAGAGAAAAA
hiNadR-end-NdeⅠ-up：CCCTCGAGTCATTGAGATGTCCCTTTTAT
Respectively using PCR amplification technology to make the DNA fragment be respectively used for the DNA fragment derived from Escherichia coli (E. coli)Escherichia coli) Salmonella typhimurium (Salmonella typhimurium) And Haemophilus influenzae: (Haemophilus influenzae) NAD synthase (a) of (b)ecNadR、 stNadR andhiNadR), then utilizing restriction enzymes Nde I and Xho I to connect the amplification product to the carrier pET-28a so as to respectively obtain the plasmid pET28a-ecNadR、pET28a- stNadR and pET28a-hiAnd NadR, the amino acid sequences of which are confirmed by sequencing to be respectively shown as SEQ ID NO: 1 to SEQ ID NO: 3, respectively.
(2) The recombinant NAD synthetase plasmid provided by the invention
Published by reference to protein databaseshiNMNAT、 hNRK1、 hNRK2、 yNRK1、 ecNRK andstthe amino acid sequence of NRK (UniProt accession numbers: P44308[52-224, respectively)]、Q9NWW6、Q9NPI5、P53915、P27278[230-410]And P2458 [230-]) Combining sequence comparison and structural function analysis to design a primer with a flexible connecting peptide segment GSGSGSGS sequencehiNMNAT andhNRK1、 hNRK2、 yNRK1、 ecNRK、 stNRK gene sequences are respectively amplified, and then amplification products are used as templates, and primers are used for amplifying the NRK gene sequenceshiNMNAT respectively withhNRK1、 hNRK2、 yNRK1、 ecNRK、 stNRK is fused with PCR to obtain the recombinant NAD synthetase provided by the inventionhihNadR1、 hihNadR2、 hiyNadR、 hiecNadR andhistthe corresponding amino acid sequences of the fusion gene segments of NadR are respectively shown in SEQ ID NO: 4 to SEQ ID NO:shown in fig. 8. Then the fusion gene fragment is connected to a vector pET-22b by utilizing restriction enzymes Nde I and Xho I to respectively obtain plasmids pET22b-hihNadR1、pET22b- hihNadR2、pET22b- hiyNadR、pET22b- hiecNadR and pET22b-histNadR。
2. Preparation of NAD synthetase enzyme solution
The NAD synthase plasmids constructed in part 1 were transformed into 50. mu.L of BL21 (DE3) competent cells, respectively, added to 900. mu.L of Luria Broth (LB) medium at 37 ℃ for activation for 1 hour, inoculated into 10-20mL of LB medium (containing 100mg/L ampicillin or 50mg/L kanamycin) for culture at 37 ℃ for 6 hours-16 hours, and then inoculated into 1-4L of LB medium (containing 100mg/L ampicillin or 50mg/L kanamycin) for culture at 37 ℃ to OD600And (4) =0.8-1, adjusting the temperature to 16-37 ℃, and adding 0.2-1mM IPTG to induce protein expression. After 4-20h, the cells were collected by centrifugation and resuspended in 20mL of a lysate (20mM Tris-HCl pH7.5, 100mM NaCl, 10mM imidazole). Then, the cells were disrupted by a homogenizer and centrifuged (4 ℃, 12000g, 25 min) to collect the supernatant.
Adding 30mL Buffer A (20mM Tris-HCl pH7.5, 100mM NaCl) balanced gravity column (30 mL column volume contains 4mL Ni-NTA gel), adsorbing for half an hour, collecting flow-through liquid containing unbound protein, washing the hybrid protein twice with 30mL Buffer B (20mM Tris-HCl pH7.5, 100mM NaCl, 20mM imidazole), incubating for 10min with 10mL Buffer C (20mM Tris-HCl pH7.5, 100mM NaCl, 500mM imidazole), collecting eluent containing bound target protein, and performing SDS-PAGE protein electrophoresis to show that the eluent is high-purity target protein, thus obtaining the NAD synthetase enzyme liquid.
3. Determination of enzymatic Activity of NAD synthetase
The enzyme solution prepared in part 2 was diluted to 1g/L after protein concentration measurement by NanoDrop 2000, and 100. mu.L of the enzyme solution was added to 400. mu.L of a reaction solution (100 mM phosphate buffer solution, pH7.2, nicotinamide ribose 10mM, ATP 20mM, MgCl, etc.)210 mM), and reacted at 37 ℃ for 15 min. After the reaction, the content of nicotinamide adenine dinucleotide in the reaction solution was measured by High Performance Liquid Chromatography (HPLC), and the results were measuredAs shown in table 1. One enzyme activity unit (U) is defined as the amount of enzyme required to convert one micromole of nicotinamide riboside per minute to nicotinamide adenine dinucleotide under the conditions described above.
TABLE 1
Enzyme solution Sequence origin Amount of NAD produced Enzyme activity U/mg
ecNadR Escherichia coli 0.2mM 0.05
stNadR Salmonella typhimurium 0.2mM 0.06
hiNadR Haemophilus influenzae 0.1mM 0.03
hihNadR1 The invention 0.8 mM 0.21
hihNadR2 The invention 7.0 mM 1.87
hiyNadR The invention 1.6 mM 0.43
hiecNadR The invention 5.9 mM 1.57
histNadR The invention 7.4 mM 1.97

Claims (8)

  1. A recombinant NAD synthase characterized by: the recombinant NAD synthase comprises a nicotinamide mononucleotide adenylyltransferase domain derived from Haemophilus influenzae and a nicotinamide ribokinase domain derived from any one of human, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium.
  2. The recombinant NAD synthase of claim 1, wherein: the nicotinamide ribokinase domain is fused at the C-terminus of the nicotinamide mononucleotide adenylyltransferase domain.
  3. The recombinant NAD synthase according to claim 1 or 2, characterized in that: the nicotinamide ribokinase structural domain is fused with the nicotinamide mononucleotide adenyl transferase structural domain through a flexible connecting peptide segment, and the sequence of the flexible connecting peptide segment is GSGSGSGS.
  4. The recombinant NAD synthase according to claim 1 or 2, characterized in that: the amino acid sequence of the nicotinamide mononucleotide adenyltransferase structural domain derived from haemophilus influenzae is the amino acid sequence with the accession number P44308[52-224] in UniProt; the amino acid sequence of the nicotinamide ribokinase domain derived from human, Saccharomyces cerevisiae, Escherichia coli and Salmonella typhimurium is the amino acid sequence with the accession numbers Q9NWW6, Q9NPI5, P53915, P27278[ 230-.
  5. The recombinant NAD synthase of claim 4, wherein: the amino acid sequence of the recombinant NAD synthetase is shown as SEQ ID NO: 4 to SEQ ID NO: shown in fig. 8.
  6. A gene sequence characterized by: the gene sequence encodes the recombinant NAD synthase of any one of claims 1-5.
  7. A biomaterial comprising a recombinant vector, a recombinant cell or a recombinant microorganism, wherein: the biological material contains the gene sequence of claim 6.
  8. Use of the recombinant NAD synthase of any one of claims 1 to 5, characterized in that: the application is that the recombinant NAD synthetase is applied to industrial production to produce NAD in a large scale by taking NR and ATP as raw materials.
CN201980044146.7A 2019-06-27 2019-06-27 Recombinant NAD synthetase, gene and application thereof Active CN112437811B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/093139 WO2020258110A1 (en) 2019-06-27 2019-06-27 Recombinant nad synthetase and gene and use thereof

Publications (2)

Publication Number Publication Date
CN112437811A true CN112437811A (en) 2021-03-02
CN112437811B CN112437811B (en) 2023-05-05

Family

ID=74060704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980044146.7A Active CN112437811B (en) 2019-06-27 2019-06-27 Recombinant NAD synthetase, gene and application thereof

Country Status (2)

Country Link
CN (1) CN112437811B (en)
WO (1) WO2020258110A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832125A (en) * 2021-10-19 2021-12-24 中山百灵生物技术股份有限公司 Nicotinamide ribokinase mutant and coding gene and application thereof
WO2023040205A1 (en) * 2021-09-14 2023-03-23 湖北远大生命科学与技术有限责任公司 Method for efficiently preparing nicotinamide mononucleotide and fusion protein

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041624A2 (en) * 2004-09-20 2006-04-20 Washington University Nad biosynthesis systems
CN102471793A (en) * 2009-07-27 2012-05-23 霍夫曼-拉罗奇有限公司 Enzymatic synthesis of CARBA-NAD
CN103710321A (en) * 2013-12-31 2014-04-09 邦泰生物工程(深圳)有限公司 Nicotinamide mononucleotide adenylyltransferase (Nmnat) mutant as well as coding gene and application thereof
WO2018023206A1 (en) * 2016-07-30 2018-02-08 邦泰生物工程(深圳)有限公司 Nicotinamide phosphoribosyltransferase mutant and application thereof
CN108998484A (en) * 2018-09-03 2018-12-14 四川百特芳华医药科技有限公司 A kind of preparation method of NADP coenzyme

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101901489B1 (en) * 2016-06-15 2018-11-02 울산대학교 산학협력단 Use of Regulator to synthesize NAD for preventing or treating the cilliopathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041624A2 (en) * 2004-09-20 2006-04-20 Washington University Nad biosynthesis systems
CN102471793A (en) * 2009-07-27 2012-05-23 霍夫曼-拉罗奇有限公司 Enzymatic synthesis of CARBA-NAD
CN103710321A (en) * 2013-12-31 2014-04-09 邦泰生物工程(深圳)有限公司 Nicotinamide mononucleotide adenylyltransferase (Nmnat) mutant as well as coding gene and application thereof
WO2018023206A1 (en) * 2016-07-30 2018-02-08 邦泰生物工程(深圳)有限公司 Nicotinamide phosphoribosyltransferase mutant and application thereof
CN108998484A (en) * 2018-09-03 2018-12-14 四川百特芳华医药科技有限公司 A kind of preparation method of NADP coenzyme

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
OLEG V. KURNASOV ET AL.: "Ribosylnicotinamide kinase domain of NadR protein: identification and implications in NAD biosynthesis", 《JOURNAL OF BACTERIOLOGY》 *
S. KUMAR SINGH ET AL.: "Crystal structure of Haemophilus influenzae NadR protein. A bifunctional enzyme endowed with NMN adenyltransferase and ribosylnicotinimide kinase activities", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
毕继才 等: "微生物NAD合成酶及其抑制剂的研究进展", 《微生物学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040205A1 (en) * 2021-09-14 2023-03-23 湖北远大生命科学与技术有限责任公司 Method for efficiently preparing nicotinamide mononucleotide and fusion protein
CN113832125A (en) * 2021-10-19 2021-12-24 中山百灵生物技术股份有限公司 Nicotinamide ribokinase mutant and coding gene and application thereof
CN113832125B (en) * 2021-10-19 2023-09-26 中山百灵生物技术股份有限公司 Nicotinamide ribokinase mutant and encoding gene and application thereof

Also Published As

Publication number Publication date
WO2020258110A1 (en) 2020-12-30
CN112437811B (en) 2023-05-05

Similar Documents

Publication Publication Date Title
JPWO2020129997A1 (en) Recombinant microorganisms and methods for producing nicotinamide derivatives, and vectors used therein.
CN110373398A (en) A kind of niacinamide ribokinase mutant and its application
CN112159831B (en) Method for preparing nicotinamide mononucleotide
CN113265382B (en) Polyphosphate kinase mutant
CN112359082B (en) Preparation method of nicotinamide mononucleotide
CN112143751B (en) Bacillus subtilis engineering bacterium for high nucleoside yield, and construction method and application thereof
CN112437811A (en) Recombinant NAD synthetase, gene and application thereof
CN110468114A (en) A kind of polyphosphate kinase RmPPK and its encoding gene and application
CN113025592A (en) High-performance polyphosphate kinase mutant and application thereof
Li et al. An artificial multi-enzyme cascade biocatalysis for biomanufacturing of nicotinamide mononucleotide from starch and nicotinamide in one-pot
CN110172454B (en) S-adenosylmethionine synthetase mutant and high-throughput screening method thereof
KR100864901B1 (en) Novel polyphosphate: amp phosphotransferase
Taran et al. Enzymatic transglycosylation of natural and modified nucleosides by immobilized thermostable nucleoside phosphorylases from Geobacillus stearothermophilus
CN113046403B (en) Method for efficiently catalyzing and synthesizing PAPS (PAPS) based on construction of ATP (adenosine triphosphate) regeneration system
CN112437813B (en) Method for industrially producing NAD (nicotinamide adenine dinucleotide) by enzyme method
KR100888513B1 (en) Novel N-Acetylglucosamine-2-Epimerase and Method for Producing CMP-neuraminic acid Using the Same
CN113755466B (en) Fructose-bisphosphatase mutants and their use in carbohydrate synthesis
Li et al. Efficient chemoenzymatic synthesis of uridine 5′-diphosphate N-acetylglucosamine and uridine 5′-diphosphate N-trifluoacetyl glucosamine with three recombinant enzymes
US20210238576A1 (en) L-aspartate alpha-decarboxylase Mutant and Application thereof
CN115725536A (en) Bifunctional enzyme, bifunctional enzyme mutant and application thereof
JP2014064513A (en) Method for preparation of 2-deoxy-scyllo-inosose
CN108795919B (en) Fusion enzyme for catalytic preparation of UDP-rhamnose and application thereof
CN110452899B (en) Glucose isomerase, mutant and application of mutant in preparation of D-fructose
CN113046402B (en) Method for synthesizing PAPS (pap) based on construction of bifunctional enzyme
CN112680482B (en) Biological preparation method of mannitol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant